However, with the contemporary introduction of paclitaxel, which provided equivalent improvements in survival, this approach was abandoned and was never implemented as a routine treatment of ovarian neoplasms 3 .
Systemic chemotherapy for peritoneal metastases is palliative; its main focus is on improving quality of life and prolonging survival. The systemic chemotherapy approach to peritoneal carcinomatosis did not yield the same survival benefit observed for hematologic and lymphatic spread; patients with peritoneal disease continued to die a few months after diagnosis 4, 5 . In the last 20 years, there has been a better understanding of carcinomatosis as part of the neoplastic spread process; it is now viewed as a disease state limited to a single "organ", the peritoneum, which has changed the outlook for treatment of this condition 6 . The combination of cytoreductive surgery and hiperthermic intraperitoneal chemotherapy (HIPEC) has since become the cornerstone of all new approaches and attempts to control peritoneal carcinomatosis 7 . Direct delivery of chemotherapeutic agents to the intraperitoneal space has proved superior to systemic chemotherapy when evaluating characteristics such Technical Note Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) through a single port: alternative delivery for the control of peritoneal metastases.
Quimioterapia Aerossolizada e Pressurizada Intraperitoneal (PIPAC) por monoportal: aplicação alternativa no controle das metástases peritoneais.
as drug concentration reached in the peritoneal space, penetration into peritoneal metastases, and chemotherapy-related toxicity 8 . The evidence which led to the use of intraperitoneal chemotherapy is based on the idea of directly exposing peritoneal metastatic nodules to drug concentrations far higher than those that can be achieved with traditional systemic chemotherapy. Direct contact between tumor cells and chemotherapeutic agents in the peritoneal cavity is associated with a tumoral biological activity that is both superior and different 
TECHNICAL NOTE Physical aspects: the operating room
Before PIPAC is attempted, the operating room requires three basic features: negativepressure, unidirectional (laminar) airflow ventilation and hermetically sealing doors. If these are not already available, the room must be prepared accordingly by the hospital engineering department. Unidirectional, or laminar, airflow should be achieved with exhaustion pumps that establish a negative flow of air between the corridor and the operating room. Hermetically sealing doors can be achieved by installing appropriate sliding doors or simply by fitting plastic sheetings around the doorframe, all the way to the floor ( Figure 1A ).
Patient monitoring must be visible outside the operating room by using a remote monitor or extension of the anesthetic monitoring screen. The control panel of the contrast injector should be available outside the operating room for activation and control. The video system should be placed to the right, at shoulder height (as for a classic laparoscopic cholecystectomy), but must be able to rotate to foot level to allow appropriate visualization of the pelvis. The infusion pump and microparticle aspirator unit should be positioned to the left of the patient. A long venous catheter with threeway stopcocks should be positioned outside the room and remain continuously accessible to the anesthesiologist throughout the procedure. Handling of cytotoxic drugs in the operating room must follow strict checking and administration protocols. All supplies that are in direct contact with the surgical field should be discarded as potentially contaminated by cytotoxic agents. On should follow the routine institutional disposal procedure for such materials. This includes surgical drapes and gowns, which, for this reason, should preferably be disposable. During handling of the chemotherapeutic agent for preparation, before administration, and upon returning to the operating room after the aerosol treatment, all individuals participating in the process must wear disposable waterproof gowns, closed-vent goggles, and respirators with a microparticulate filter ( Figure 1B) . agent is checked and loaded into the power injector, which is then prepared for delivery. All staff then leave the operating room, which should be closed by a hermetically sealing sliding door or sealed with plastic sheeting. The injector must be set to administer the volume calculated and compounded by the pharmacy. The infusion rate should be set to 3ml/s, and must not exceed a pressure of 300psi. Once aerosolization is completed, an intraperitoneal pressure of 12mmHg must be maintained for a period of 30 minutes (therapeutic pneumoperitoneum). After the therapeutic pneumoperitoneum period is complete, all staff return to the operating room, wearing personal protective equipment (disposable waterproof apron, dust and mist respirator equipped with a nuisance-level organic vapor filter, and eye protection). The insufflator is shut off. The aerosolized chemotherapy is suctioned through a filter into the aspirator unit. The 10-mm scope is removed. The plastic cover is opened and the BhioQap system is removed. The cavity is inspected and the abdominal wall is closed in conventional fashion, with interrupted Prolene and Monocryl 4-0 sutures.
DISCUSSION
In the setting of peritoneal carcinomatosis, PIPAC has emerged as a promising approach to a condition that still carries a guarded prognosis.
It should not be understood as an alternative to the already established combination approach of cytoreductive surgery with hyperthermic chemotherapy. PIPAC seems to be more appropriate for patients who do not benefit from this aggressive surgical approach to the treatment of carcinomatosis. The single-port procedure described herein explores the concept of reducing the possibility of abdominal wall implants, and was first described by Robella et al. 15 . The understanding of carcinomatosis as a chronic process of inflammation and implantation of neoplastic cells in the peritoneal cavity gave rise to the concept of "tumor cell entrapment". The single-port procedure, even though it is probably associated with greater inflammation than conventional laparoscopy, as suggested in previous studies 16 The key distinctive feature of PIPAC is the process of converting a liquid solution of chemotherapy into an aerosolized spray, thereby potentiating its effects, when aerosolized liquids take on the general physical characteristics, behavior, and distribution of a gas. Two of these properties are essential for the application of intraperitoneal chemotherapy. The first is a homogeneous and rapid distribution in the physical space within which the gas is contained.
This property has been challenged in studies demonstrating that the drug concentrations achieved are close to those obtained with the conventional delivery model 17 This consolidates the concept of therapeutic pneumoperitoneum as a mechanism superior to all other modalities for delivery of intraperitoneal chemotherapy used to date. Hence, the use of therapeutic pneumoperitoneum may explain the encouraging initial results obtained with PIPAC in the treatment of peritoneal carcinomatosis secondary to gastric cancer 18 , colon cancer 21 , and ovarian cancer 14 . Neoadjuvant use of PIPAC may be a promising approach for these patients, and may allow debulking of high-PCI peritoneal carcinomatosis to a more localized disease state, which may then be amenable to cytoreductive surgery with hyperthermic chemotherapy 22 .
In summary, encouraging initial data suggest that PIPAC can improve quality of life in a significant number of patients with peritoneal carcinomatosis, and is a potential tool for palliative treatment of patients with peritoneal metastases 23 .
The response rates reported thus far are still based on small, retrospective cohort or case-control studies. Nevertheless, the unique features of PIPAC described above lead us to believe that this technique holds promise for the treatment of peritoneal carcinomatosis, and that the available evidence for its utility should not be disregarded.
A carcinomatose peritoneal é a evolução natural das neoplasias gastrointestinais, ginecológicas e primárias do peritônio. Nos últimos anos, a carcinomatose passou a ser considerada uma doença confinada ao peritônio, e não mais uma doença disseminada. Desta forma, a associação de citorredução cirúrgica associada à quimioterapia intraperitoneal se tornou o ponto chave no controle das metástases peritoneais. Tradicionalmente, a quimioterapia intraperitoneal é aplicada utilizando soluções líquidas. Uma nova modalidade de infusão da quimioterapia na cavidade abdominal surge como uma alternativa ao método tradicional. A chamada PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy) transforma a solução terapêutica líquida em um spray aerossolizado, potencializando a distribuição e penetração da quimioterapia intraperitoneal. Este relato tem por objetivo descrever essa nova técnica cirúrgica inovadora, realizada pela primeira vez por um monoportal no Brasil, alterando a forma descrita originalmente para a aplicação da PIPAC.
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